Back to Home Page

LDTs in Immuno-Oncology Workshop:
Translating Cancer Research into Targeted Therapeutics

Click for Recordings
Thursday, October 13, 2016 - 11:00am EDT
This webinar is presented as a preview to the Companion Diagnostics Symposium coming in November.

In this Webinar...

Presenters will focus on cancer and immune surveillance and strategies that diagnostic laboratories can use to translate science into practice.  In addition to the underlying science, we will focus on practical aspects of  PD-L1 testing and use it as a case study of emerging complexity in biomarker diagnostics.  We will discuss role of  LDTs in clinical practice and clinical trials. Many shades (intensity) of PD-L1 are detected by different antibody clones using different IHC platforms, therefore close attention must be paid to reagents and measurement systems: know your biomarkers!

Click Here to visit the Companion Diagnostics Symposium Homepage



Kamala Maddali, DVM, Ph.D.
Vice President
Biopharma Collaborations & Companion Diagnostics
Cancer Genetics, Inc.


Rita Shaknovich, MD, Ph.D.
Medical Director & Vice President of Hematopathology
Cancer Genentics, Inc.


Dr. Rita Shaknovich... 

Dr. Kamala Maddali...

Brings over 10 years of experience in Pathology, Hematopathology, and Surgical Pathology. Dr. Shaknovich is a physician scientist with clinical expertise in Hematopathology and extensive experience in translational research and experimental therapeutics. The focus of her research has been in epigenetic mechanisms governing normal B cell development and lymphomagenesis. Her Ph.D. work and her postdoctoral training focused on pathobiology of hematologic malignancies. Her laboratory in WCMC studied epigenetic mechanisms of gene regulation during normal B cell development and epigenetic changes that contribute to neoplastic transformation. Her research was funded by such agencies as NIH, STARR Cancer Consortium, Leukemia and Lymphoma Foundation (LLF) and Lymphoma Research Foundation (LRF). Her lab used genome-wide approaches to profile genome, transcriptome and methylome of B cells at different stages of development and of different subtypes of Lymphomas in order to identify novel epigenetic mechanisms of neoplastic transformation. Dr. Shaknovich has published multiple peer reviewed publications, invited reviews, and invited book chapters, as well as conducted global lectures and presentations on lymphomas.

Dr. Shaknovich received her MD and PhD degrees from the Medical Scientist training program in Mount Sinai School of Medicine in New York, after which she completed clinical training in Anatomic Pathology specializing in Hematopathology and finished her post-doctoral training in the laboratory of Dr. Ari Melnick in Weill Cornell Medical College (WCMC).



Joined CGI in 2015, and plays a pivotal role in the biomarker and companion diagnostics strategy in the context of pharma novel drug development programs.

Dr. Maddali brings over 10 years of extensive experience of global P&L scientific and commercial management of clinical biomarker and companion diagnostics (CDx) services covering personalized medicine strategy. She has promoted the proper utilization of biomarkers, personalized medicine and diagnostics in drug development and patient management to bridge the gap between drug and diagnostic industries. She was Global Director Scientific Development -Biomarkers & Companion Diagnostics for Q2 Solutions (A Quintiles & Quest Diagnostics joint venture). She brings a lot of strategic values from her previous roles at Quest Diagnostics, Quintiles and Merck Schering Plough in the arena of biomarkers and companion diagnostics.

Dr. Maddali holds a DVM Ph.D., in Pharmacology from University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India.